Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inherited Neuropathies Clear all
Terminated Phase 2 Interventional Results available

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Safety Study of Idebenone to Treat Friedreich's Ataxia

NCT00015808
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Idebenone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2006 · Synced Oct 17, 2026, 9:58 AM EDT
Terminated Phase 4 Interventional Results available

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 17, 2026, 9:58 AM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 17, 2026, 9:58 AM EDT
Terminated Phase 1 Interventional

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

NCT04586335
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
Interventions
CYH33
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
New Haven, Connecticut • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Not applicable Interventional

High Intensity Exercise and Improving Physical Activity Among People With Neurologic Dysfunction

NCT06945835
View directory record Official record
Conditions
Cerebral Palsy (CP), Stroke, Spinal Cord Injury, Traumatic Brain Injury, Charcot Marie Tooth Disease (CMT), Spina Bifida
Interventions
Participate in high intensity exercise of at least 20 minutes in 60 minutes session of RPE greater than 6.
Behavioral
Lead sponsor
University of Hartford
Other
Eligibility
8 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
West Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 17, 2026, 9:58 AM EDT
Recruiting No phase listed Observational

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619
View directory record Official record
Conditions
Melanoma
Interventions
Single agent, adjuvant anti-PD1 therapy
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia

NCT01987219
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Albuterol-sulphate, Ipratropium-bromide, placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

NCT03126019
View directory record Official record
Conditions
Lymphoma
Interventions
Parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 17, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

NCT02718300
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Parsaclisib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Early Phase 1 Interventional

PET/MRI Evaluation of Cardiac Amyloid

NCT03119558
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
18F-Florbetaben (Neuraceq®) PET/MRI
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

NCT01070316
View directory record Official record
Conditions
Epilepsy, Tuberous Sclerosis Complex
Interventions
Everolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 17, 2026, 9:58 AM EDT
Recruiting Phase 1 Interventional

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

NCT07543991
View directory record Official record
Conditions
Giant Axonal Neuropathy (GAN)
Interventions
scAAV9/JeT-GAN
Genetic
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 17, 2026, 9:58 AM EDT
Suspended Phase 1Phase 2 Interventional

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04278768
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Emavusertib, Venetoclax
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

NCT04768296
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Berzosertib, Topotecan
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Santa Rosa, California • Topeka, Kansas • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 17, 2026, 9:58 AM EDT
Completed No phase listed Observational Results available

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

NCT04285723
View directory record Official record
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)
Interventions
alpelisib
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 17, 2026, 9:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Electrical Impedance Myography (EIM) in ALS

NCT02011204
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Marie-Tooth Disease, Multiple Sclerosis
Interventions
Electrical impedance myography (EIM)
Device
Lead sponsor
Skulpt, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 17, 2026, 9:58 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biomechanics of Optic Neuropathy

NCT02982499
View directory record Official record
Conditions
Optic Neuropathy
Interventions
magnetic resonance image (MRI), Optical Coherence Tomography (OCT)
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 17, 2026, 9:58 AM EDT
Recruiting Not applicable Interventional

Exercise Training in Transthyretin Cardiac Amyloidosis

NCT05797857
View directory record Official record
Conditions
Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Interventions
Exercise Training
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 17, 2026, 9:58 AM EDT
Enrolling by invitation Phase 2 Interventional

Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

NCT06148311
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Matching placebo, Dexmedetomidine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional

Study of PX-866 and Docetaxel in Solid Tumors

NCT01204099
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Docetaxel, PX-866
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
29
States / cities
Birmingham, Alabama • Escondido, California • Pleasant Hill, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 17, 2026, 9:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

NCT01193088
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease, Type Ia (Disorder), HMSN
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
Not listed
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2030
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 9:58 AM EDT
Active, not recruiting Phase 2 Interventional

Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

NCT06128356
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Dexmedetomidine Sublingual
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 9:58 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis

NCT05619302
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
[68Ga]CBP8 PET/MRI
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 17, 2026, 9:58 AM EDT